Evidence map›Paper›PMID 37676470›Full record

ArticleDermatology and therapy2023

Rapid Remission of Sunburn-Induced Guttate Psoriasis with Guselkumab.

Erin Bartholomew, Bo-Young Chung, Mitchell Davis, Samuel Yeroushalmi, Mimi Chung, Marwa Hakimi, Tina Bhutani, Wilson Liao

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Dermatology and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Management of Guttate Psoriasis: A Systematic Review.Journal of cutaneous medicine and surgery
    Pooled it
  2. Article
  3. Review
  4. Guselkumab - In Psoriasis and Beyond.Dermatology practical & conceptual · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 2 countries.

Erin Bartholomew *Department of Dermatology, The University of California, San Francisco (UCSF), 2340 Sutter Street, Box 0808, San Francisco, CA, 94115, USA.
Bo-Young Chung *Department of Dermatology, The University of California, San Francisco (UCSF), 2340 Sutter Street, Box 0808, San Francisco, CA, 94115, USA.
Mitchell DavisDepartment of Dermatology, The University of California, San Francisco (UCSF), 2340 Sutter Street, Box 0808, San Francisco, CA, 94115, USA.
Samuel YeroushalmiDepartment of Dermatology, The University of California, San Francisco (UCSF), 2340 Sutter Street, Box 0808, San Francisco, CA, 94115, USA.
Mimi ChungDepartment of Dermatology, The University of California, San Francisco (UCSF), 2340 Sutter Street, Box 0808, San Francisco, CA, 94115, USA.
Marwa HakimiDepartment of Dermatology, The University of California, San Francisco (UCSF), 2340 Sutter Street, Box 0808, San Francisco, CA, 94115, USA.
Tina BhutaniDepartment of Dermatology, The University of California, San Francisco (UCSF), 2340 Sutter Street, Box 0808, San Francisco, CA, 94115, USA.
Wilson LiaoDepartment of Dermatology, The University of California, San Francisco (UCSF), 2340 Sutter Street, Box 0808, San Francisco, CA, 94115, USA. wilson.liao@ucsf.edu.ORCID http://orcid.org/0000-0001-7883-6439
University of California, San Francisco · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Guselkumab is an anti-interleukin-23 monoclonal antibody that is approved for plaque psoriasis and psoriatic arthritis. We present a case of a 28-year-old female patient with acute onset of guttate psoriasis after a blistering sunburn. She had no personal or family history of psoriasis or chronic inflammatory skin disease. The guttate psoriasis was refractory to topical treatment. After the first dose of guselkumab (100 mg subcutaneous injection), the patient experienced near-clearance of her guttate psoriasis, with continued improvement and drug-free remission 8 months after cessation of treatment. Dermatologists could consider guselkumab as a treatment option for patients with guttate psoriasis. Future studies should examine the potential for guselkumab to induce drug-free remissions in guttate psoriasis.

Indexed as

Anti-IL23GuselkumabGuttate psoriasisMonoclonal antibodyRemissionSunburn

Identifiers

PMID37676470
PMCPMC10539232
OpenAlexW4386502324

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.